Biodexa Pharmaceuticals annual depreciation and amortization
2015
2016
2017
2018
2022
2023
2024
2025
Biodexa Pharmaceuticals Depreciation & Amortization Growth & History (BDRX)
Biodexa Pharmaceuticals's depreciation and amortization was £189,000 for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £189,000 | −£65,000 | −25.59% |
| 2024 | 2024-12-31 | £254,000 | −£29,000 | −10.25% |
| 2023 | 2023-12-31 | £283,000 | −£60,000 | −17.49% |
| 2022 | 2022-12-31 | £343,000 | — | — |
| 2018 | 2018-12-31 | £133,000 | £71,000 | +114.52% |
| 2017 | 2017-12-31 | £62,000 | £40,000 | +181.82% |
| 2016 | 2016-12-31 | £22,000 | −£4,000 | −15.38% |
| 2015 | 2015-12-31 | £26,000 | — | — |
Biodexa Pharmaceuticals depreciation and amortization trends
Between the periods ended 2015-12-31 and 2025-12-31, Biodexa Pharmaceuticals's depreciation and amortization increased from £26,000 to £189,000, a change of £163,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...